Suppression of high-mobility group box-1 and receptor for advanced glycation end-product axis by polymyxin B-immobilized fiber hemoperfusion in septic shock patients

Journal of Critical Care

Volumn 26, Issue 6, 2011, Pages 546-549

  Nakamura, Tsukasa ^a   Sato, Eiichi ^a   Fujiwara, Nobuharu ^a   Kawagoe, Yasuhiro ^a   Maeda, Sayaka ^b   Yamagishi, Sho ichi ^b  

^a Shinmatsudo Central General Hospital   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Endotoxin; HMGB1; PMX F; Septic shock; SRAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 6; POLYMYXIN B; POLYSTYRENE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG MECHANISM; ENDOTOXIN DETECTION; FEMALE; HEMOPERFUSION; HUMAN; MALE; SEPTIC SHOCK; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; ENDOTOXINS; FEMALE; HMGB1 PROTEIN; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; POLYMYXIN B; RECEPTORS, IMMUNOLOGIC; SHOCK, SEPTIC;

EID: 80052964021     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2010.11.010     Document Type: Article

References (23)

1. Winters B.D., Eberlein M., Leung J., et al. Long-term mortality and quality of life in sepsis: a systematic review. Crit Care Med 2010, 38:1276-1283.
2. Nakamura T., Yamagishi S.I. PEDF and septic shock. Curr Mol Med 2010, 10:312-316.
3. Cohen J. Non-antibiotic strategies for sepsis. Clin Microbiol Infect 2009, 15:302-307.
4. Shoji H., Tani T., Hanasawa K., et al. Extracorporeal endotoxin removal by polymyxin B immobilized fiber cartridge: designing and antiendotoxin efficacy in the clinical application. Ther Apher 1998, 2:3-12.
5. Tani T., Hanasawa K., Kodama M., et al. Correlation between plasma endotoxin, plasma cytokines, and plasminogen activator inhibitor-1 activities in septic patients. World J Surg 2001, 25:660-668.
6. Vincent J.L., Laterre P.F., Cohen J., et al. A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 2005, 23:400-405.
7. Klune J.R., Dhupar R., Cardinal J., et al. HMGB1: endogenous danger signaling. Mol Med 2008, 14:476-484.
8. Wang H., Bloom O., Zhang M., et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248-251.
9. Gibot S., Massin F., Cravoisy A., et al. High-mobility group box 1 protein plasma concentrations during septic shock. Intensive Care Med 2007, 33:1347-1353.
10. Gaini S., Pedersen S.S., Koldkjaer O.G., et al. High mobility group box-1 protein in patients with suspected community-acquired infections and sepsis: a prospective study. Crit Care 2007, 11:R32.
11. Van Zoelen M.A.D., van der Poll T. Targeting RAGE in sepsis. Crit Care 2008, 12:103.
12. Bopp C., Bierhaus A., Hofer S., et al. Bench-to-bedside review: the inflammation-perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis. Crit Care 2008, 12:201.
13. Yamagishi S., Matsui T. Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front Biosci 2010, 2:1184-1195.
14. Moser B., Hudson B.I., Schmidt A.M. Soluble RAGE: a hot new biomarker for the hot joint?. Arthritis Res Ther 2005, 7:142-144.
15. Nakamura T., Sato E., Fujiwara N., et al. Circulating levels of advanced glycation end products (AGE) and interleukin-6 (IL-6) are independent determinants of serum asymmetric dimethylarginine (ADMA) levels in patients with septic shock. Pharmacol Res 2009, 60:515-518.
16. Bopp C., Hofer S., Weitz J., et al. sRAGE is elevated in septic patients and associated with patients outcome. J Surg Res 2008, 147:79-83.
17. American College of Chest Physicians/Society of Critical care Medicine Consensus Conference Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20:864-874.
18. Nakamura T., Kawagoe Y., Matsuda T., et al. Effect of polymyxin B immobilized fiber on bone resorption in patients with sepsis. Int Care Med 2004, 30:1838-1841.
19. Watanabe E., Hirasawa H., Oda S., et al. Extremely high interleukin-6 blood levels and outcome in the critically ill are associated with tumor necrosis factor-and interleukin-1-related gene polymorphisms. Crit Care Med 2005, 33:89-97.
20. Chen P., Li J., Barnes J., et al. Restraint of proinflammatory cytokine biosynthesis by mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages. J Immunol 2002, 169:6408-6416.
21. Hussein M.H., Kato T., Sugiura T., et al. Effect of hemoperfusion using polymyxin B-immobilized fiber on IL-6, HMGB-1, and IFN gamma in a neonatal sepsis model. Pediatr Res 2005, 58:309-314.
22. Kanesaka S., Sasaki J., Kuzume M., et al. Effect of direct hemoperfusion using polymyxin B immobilized fiber on inflammatory mediators in patients with severe sepsis and septic shock. Int J Artif Organs 2008, 31:891-897.
23. Shimizu T., Hanasawa K., Sato K., et al. Direct hemoperfusion with polymyxin-B-immobilized fiber columns improves septic hypotension and reduces inflammatory mediators in septic patients with colorectal perforation. Langenbecks Arch Surg 2009, 394:303-311.